M-9140
- Generic Name
- M-9140
Anti-CEACAM5 ADC M9140 in Chinese Participants With Solid Tumors (PROCEADE-CRC-02)
- First Posted Date
- 2025-02-03
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 24
- Registration Number
- NCT06806046
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
🇨🇳The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
Phase 1
Recruiting
- Conditions
- Solid TumorsPancreatic CancerGastric CancerPancreatic Ductal Adenocarcinoma (PDAC)Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2024-11-29
- Last Posted Date
- 2025-05-07
- Target Recruit Count
- 250
- Registration Number
- NCT06710132
- Locations
- 🇯🇵
Saiseikai Kumamoto Hospital - 300175708, Kumamoto-shi, Japan
🇰🇷Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
Phase 1
Recruiting
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2025-05-07
- Target Recruit Count
- 200
- Registration Number
- NCT05464030
- Locations
- 🇺🇸
California Cancer Associates for Research & Excellence, Inc., Fresno, California, United States
🇺🇸Rhode Island Hospital, Providence, Rhode Island, United States
🇺🇸Mary Crowley Cancer Research, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath